T1	p 191 211	herpes zoster ( HZ )
T2	p 262 297	individuals > or =60 years of age .
T3	p 476 548	subjects > or =50 years of age . Subjects with a negative history for HZ
T4	p 613 689	Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years ) .
T5	i 98 143	refrigerator-stable formulation of Zostavax .
T6	i 148 164	vaccine Zostavax
T7	i 357 414	refrigerator-stable formulation ( Zostavax refrigerated )
T8	i 433 472	current formulation ( Zostavax frozen )
T9	i 1109 1121	refrigerated
T10	i 1138 1144	frozen
T11	i 1269 1316	( refrigerated formulation/frozen formulation )
T12	i 1638 1677	refrigerated and the frozen formulation
T13	i 1870 1913	refrigerator-stable formulation of Zostavax
T14	i 1976 1996	frozen formulation ;
T15	o 322 328	safety
T16	o 337 351	immunogenicity
T17	o 690 696	Safety
T18	o 741 790	Varicella-zoster virus ( VZV ) antibody responses
T19	o 902 952	VZV antibody geometric mean titer ( GMT ; day 28 )
T20	o 959 1014	VZV antibody geometric mean rise ( GMR ; days 1 to 28 )
T21	o 1025 1089	incidence of vaccine-related serious adverse experiences ( AEs )
T22	o 1186 1190	GMTs
T23	o 1249 1316	estimated GMT ratio ( refrigerated formulation/frozen formulation )
T24	o 1376 1380	GMRs
T25	o 1424 1451	vaccine-related serious AEs
T26	o 1492 1507	safety profiles
T27	o 1557 1590	frequencies of injection-site AEs
T28	o 1732 1759	frequencies of systemic AEs
T29	o 1806 1825	vaccine-related AEs
T30	o 1932 1946	safety profile
T31	o 1957 1968	immunogenic